How does ivermectin overdose interact with other medications or genetic factors to worsen neurological outcomes?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin neurotoxicity is uncommon at therapeutic doses because the drug is actively excluded from the brain by the P‑glycoprotein (ABCB1/MDR1) efflux pump, but overdose or disruption of that protection — by genetic loss-of-function variants or by drug interactions that inhibit P‑glycoprotein or CYP3A4 metabolism — can let ivermectin accumulate in the CNS and produce confusion, ataxia, seizures, coma and other neurologic outcomes [1] [2] [3]. Reports place such serious events as rare overall, but they cluster where host factors (ABCB1 mutations), co‑administered inhibitors, massive dosing, or Loa loa co‑infection are present, so the interaction between overdose and other medications or genetics materially increases risk [4] [5] [6].
1. How ivermectin normally avoids the brain — the protective pump
Ivermectin is largely kept out of the central nervous system in humans by ATP‑dependent P‑glycoprotein transporters encoded by ABCB1 (also called mdr‑1), which sit at the blood‑brain barrier and actively efflux the drug back into the blood, explaining why routine therapeutic use has been largely free of neurologic adverse events [1] [2] [3].
2. Overdose overwhelms transport: saturation that permits CNS entry
When ingested in massive amounts the transporter capacity can be saturated and ivermectin may cross into the CNS, producing GABA‑ergic and other receptor‑mediated effects — clinically manifesting as somnolence, ataxia, tremor, hypotension, seizures and coma — a pattern documented in human overdose case reports and toxicology series [7] [8] [9] [3].
3. Genetic vulnerability: ABCB1/ABCB1 nonsense mutations and rare human susceptibilities
Animal models and veterinary experience (e.g., collies homozygous for an ABCB1 nonsense mutation) show dramatic sensitivity to ivermectin at doses that are harmless in other animals, and human case reports and genetic analyses implicate rare ABCB1 loss‑of‑function mutations that can produce toxicity even at therapeutic doses, making host genotype an important but rare risk factor [5] [8] [3].
4. Drug–drug interactions that raise brain exposure: P‑gp and CYP3A4 inhibitors
Co‑administration of drugs or even foods that inhibit P‑glycoprotein can reduce efflux at the blood‑brain barrier, while inhibitors of CYP3A4 can increase systemic ivermectin levels; either pathway can convert a tolerated dose into a neurotoxic one, and the literature explicitly flags concomitant use of CYP3A4 inhibitors or P‑gp inhibitors as mechanisms for serious adverse events beyond parasitic co‑infections [6] [2] [1].
5. Confounders and special cases: Loa loa and mass‑treatment settings
Large series from mass administration campaigns show severe encephalopathies in people with very high Loa loa microfilarial loads after ivermectin, reminding that not all post‑ivermectin neurologic events are simple pharmacologic toxicity; disentangling parasite‑related inflammatory encephalopathy from drug‑induced neurotoxicity is a recurring challenge in pharmacovigilance [4] [10].
6. Clinical consequences and management implications
Clinically, reported ivermectin neurotoxicity ranges from confusion and ataxia to seizures and coma, with care largely supportive and case reports describing use of activated charcoal or symptomatic ICU management; pharmacovigilance reviews emphasize that most serious events are rare but that inappropriate high‑dose use (for example during COVID‑19) has produced more hospitalizations [9] [3] [11].
7. Balance of evidence and remaining unknowns
The available literature converges: serious neurologic outcomes from ivermectin are uncommon overall, but risk rises when overdose overwhelms efflux pumps, when rare ABCB1 mutations impair the barrier, or when co‑medications inhibit P‑gp or CYP3A4 — yet the frequency and full genetic spectrum of human ABCB1 variants that confer clinically significant susceptibility remain incompletely characterized and warrant targeted investigation [1] [5] [2] [6].